Cryo-Cell International filings document material events, governance matters, financing arrangements and exchange-listing compliance for a cord blood banking and cryogenic storage company. Recent 8-K reports cover NYSE American continued-listing standards, dividend determinations, annual meeting timing, and Regulation FD disclosures tied to company announcements.
The filing record also includes definitive proxy materials for director elections, auditor ratification, executive compensation voting and stockholder meeting procedures. Financing disclosures describe amendments to the company’s Susser Bank credit agreement, including revolving credit and term loan arrangements, subsidiary guarantor provisions involving Celle Corp., maturity terms, interest-rate mechanics and related security documents.
Cryo-Cell International, Inc. reported results from its October 27, 2026 annual meeting, where stockholders voted on four director candidates, auditor ratification and a non-binding advisory resolution on named executive officer compensation. David Portnoy received 6,474,964 votes for and 1,215,273 withheld; Harold Berger received 7,121,908 for and 568,329 withheld; Mark Portnoy received 6,496,862 for and 1,193,375 withheld; and Daniel Mizrahi received 7,152,068 for and 538,169 withheld.
WIPFLI LLC’s appointment as independent registered public accounting firm for the fiscal year ending November 30, 2026 received 7,578,019 votes for, 4,178 against and 108,040 abstentions. The executive-compensation resolution received 6,661,012 votes for, 1,028,359 against and 866 abstentions. A separate authorization concerning proxies on other properly presented business received 6,513,018 votes for, 515,442 against and 661,777 abstentions.
Cryo Cell International Inc. director Daniel Mizrahi was granted 5,300 stock options on October 27, 2026, with a $4.9600 exercise price. The options vest at a rate of 1/12 per month commencing on October 27, 2026, and expire October 27, 2036. Direct common-stock holdings were 30,634 shares as of October 27, 2026; five other direct option positions, each covering 5,300 common shares, are also listed.
Cryo-Cell International Inc. director Harold D. Berger received a grant of 5,300 stock options on October 27, 2026, with a $4.96 per-share exercise price and an expiration date of October 27, 2036. The options vest at a rate of 1/12 per month commencing on October 27, 2026. The filing also lists 57,901 directly held common shares and an existing option covering 7,500 common shares at a $7.53 exercise price, expiring August 30, 2029.
Cryo-Cell International, Inc. (CCEL) is soliciting votes at its October 27, 2026 annual meeting on four director nominees—David I. Portnoy, Mark L. Portnoy, Harold D. Berger and Daniel Mizrahi—ratification of Wipfli LLP’s appointment for fiscal 2026, a non-binding advisory vote on named executive compensation, and other business. Holders of record on September 21, 2026 may vote one share on each matter; 8,062,650 common shares were outstanding on that date. The Board recommends “FOR” the nominees, auditor ratification and compensation resolution.
For fiscal 2025, reported total compensation was $1,618,516 for Co-CEO David I. Portnoy and $1,085,418 for Co-CEO Mark L. Portnoy. Cryo-Cell reported a net loss of $2.429 million in fiscal 2025, compared with net income of $402,000 in fiscal 2024. The say-on-pay vote is non-binding, and the Compensation Committee says it will consider the result in future compensation decisions. The ownership table reports 3,442,514 shares, or 39.93%, beneficially owned by current directors and executive officers as a group as of September 21, 2026.
Cryo-Cell International reported third-quarter revenue of $7,824,156, compared with $7,825,432 a year earlier, while net income rose to $1,270,490 from $749,408. For the nine months ended August 31, 2026, revenue was $23,283,386 versus $23,723,155 and net income was $1,872,184 versus $1,388,048.
Nine-month operating income was $4,156,206, down from $4,449,181, and operating cash flow was $3,639,507, compared with $4,197,793. Cash and cash equivalents totaled $1,425,663 at August 31, 2026. The revolving line of credit balance was zero, versus $2,300,000 at November 30, 2025.
Deferred revenue, including payments received before services are performed, totaled $63,972,130 at August 31, 2026; $9,719,618 was to be recognized over the next 12 months. Cryo-Cell reported receiving Duke's notice of termination of the license agreement effective May 17, 2025, and said it is unlikely to commercialize the licensed rights or otherwise obtain the agreement's benefits. The arbitration hearing concluded in late July 2026, and the company anticipates a final ruling by the end of calendar year 2026.
Cryo-Cell International, Inc. (CCEL) announced the schedule for its 2026 Annual Meeting of Stockholders. The Board of Directors set October 27, 2026 as the meeting date and September 21, 2026 as the record date for determining which stockholders are entitled to receive notice of and vote at the meeting.
The company also noted that, under its Bylaws, the deadlines for stockholders to submit proposals of business or director nominations for consideration at the 2026 Annual Meeting were both July 27, 2026. These deadlines have already passed.
Cryo-Cell International Inc. Chairman and Co-CEO David Portnoy restructured his holdings on August 5, 2026 by transferring 600,191 common shares to the David Portnoy Irrevocable 2026 Trust Agreement. The trust borrowed $800,000.26, used to satisfy Portnoy’s indebtedness, and he personally guaranteed repayment. The reported $1.3329 per share value is simply the loan amount divided by the transferred shares and not their fair market value. Portnoy is not a beneficiary of the trust, cannot revoke it and, for Section 16 purposes, disclaims beneficial ownership of its shares except for any pecuniary interest. After the transfer he directly holds 247,438 shares, has several indirect positions, and retains stock options including 280,000 underlying shares at $12.27 and 150,000 underlying shares at $3.89 per share.
Camac Fund and related entities filed an amended Schedule 13D reporting a significant stake in Cryo-Cell International. Camac Fund beneficially owns 551,081 shares of Cryo-Cell common stock, representing approximately 6.8% of the 8,055,150 shares outstanding as of April 14, 2026. The fund acquired these shares for an aggregate purchase price of about $1,807,998 using working capital, which may include margin loans.
The reporting group, including Camac Partners, Camac Capital and manager Eric Shahinian, states it bought the shares because it viewed them as undervalued and an attractive investment. They indicate they may increase or decrease their position and may engage with Cryo-Cell’s management and board on topics such as board composition, corporate governance, spending levels, asset monetization and returning capital to shareholders.